Company intelligence / Profile preview

Limedion

Heidelberg, Baden-Württemberg, Germany

Ownership: Private
Development stage: Other

Overview

Limedion is a German biotechnology company focused on developing next-generation gene editing therapies based on Prime Editing technology. Spun out from Heidelberg University, the company aims to improve the efficiency, safety, and delivery of search-and-replace genomic tools to treat a variety of inherited diseases. Their proprietary approach addresses the limitations of first-generation CRISPR systems by enabling precise DNA corrections without requiring double-strand breaks. Limedion is currently in the pre-clinical phase, advancing a pipeline of candidates for genetic disorders with high unmet medical needs.

Therapeutic areas: Rare DiseasesMetabolic Disorders
Modalities: CRISPR-based therapyGene therapyPrime editing
Industry: Biotech

Beyond the preview

Go deeper on Limedion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Limedion.

Explore the full profile